ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly immunology — Worldwide revenue ($M) [legacy total] ($M)
Form 10-Q / 10-K Note 2
Latest, Q2 2026
1,417
Period ended Jun 30, 2026
Change on a year earlier
+12.8%
1,256 in Q2 2025
History
30 quarters
Since Q1 2017
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology — Worldwide revenue ($M) [legacy total] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,417 | +12.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,203 | +10.6% | Form 10-Q (filed 2026-04-30) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,362 | +14.9% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,256 | +16.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,088 | +30.5% | Form 10-Q (filed 2026-04-30) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,186 | +20.1% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,082 | +16.6% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 834 | +7.2% | Form 10-Q (filed 2025-05-01) ↗ |
| Q3 2023 | Sep 30, 2023 | 987 | +13.9% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 929 | +16.6% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 778 | +4.0% | Form 10-Q (filed 2024-04-30) ↗ |
| Q3 2022 | Sep 30, 2022 | 866 | -13.8% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 797 | +1.4% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 748 | +21.9% | Form 10-Q (filed 2023-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,005 | +60.2% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 785 | +43.2% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 614 | +4.8% | Form 10-Q (filed 2022-04-29) ↗ |
| Q3 2020 | Sep 30, 2020 | 627 | +37.9% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 548 | +20.2% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 586 | +75.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q3 2019 | Sep 30, 2019 | 455 | +42.3% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 456 | +72.3% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 335 | +87.3% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 320 | +90.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 265 | +84.5% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 179 | +81.4% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 196 | – | Form 10-K (filed 2018-02-20) ↗ |
| Q3 2017 | Sep 30, 2017 | 168 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 144 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 98.5 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Immunology — Worldwide revenue ($M) [legacy total] ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_immunology_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.